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“Developing a Transformative Drug Policy Research Agenda in the United States”  
 
Abstract 
Despite its strengths, drug policy scholarship in the United States has deficiencies and systemic biases 
that contribute to misinformation about drugs and people who use drugs. Factors ranging from funders’ 
biases to an over-emphasis on abstinence-only or prohibition-related outcomes limit the scope and focus 
of drug policy research. These deficiencies, combined with the highly-politicized nature of drug policy 
reform, have led U.S. decision makers to largely reproduce the uninformed thinking that epitomizes failed 
drug policies. In an effort to address some of the limitations in drug policy research, we designed 
Unbounded Knowledge: Envisioning a New Future for Drug Policy Research, a project to engage 
researchers in thinking about how U.S. drug policy research should be transformed. The project involved 
a diverse group of multidisciplinary drug researchers and clinicians in a focused collaboration to identify 
what drug research should be—but is not—studying in the U.S.  It consisted of three distinct parts: 1) a 
preliminary series of interviews with researchers, 2) the identification of common research constraints and 
a set of factors that would transform the direction of drug policy research in the U.S. and, 3) a day-long 
workshop to craft an aspirational research agenda built on this foundation. In this article, we report on the 
project, particularly its emphasis on how to better inform research deficiencies through a collaborative, 
innovative research agenda. Participants were broadly in consensus that significant changes are needed to 
create different ways to conduct drug policy research and new opportunities within the drug research 
environment. They also generated specific ideas for research that could better shape U.S. drug policies in 
ways that move beyond the dominant focus on criminalization and medicalization. This article offers 
detailed recommendations generated by the project for improving drug policy research in the U.S. 
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Introduction  
 Drug policy in the United States has been influenced by multiple forces, including 
medicalization, harm reduction, and decriminalization, but among them prohibition remains dominant.  
Researchers in the U.S. have produced a breadth of high quality work in this context, and yet the narrow 
prohibitionist framework of American drug policy continues to influence and constrain the research it 
helps fund and produce. Some U.S. scholars note that drug policy research can manifest assumptions, 
deficiencies, and systemic biases that contribute to misinformation about drugs and people who use drugs. 
(Netherland, 2016; Kilmer, et al., 2012; Kleinman et al., 2012; Brownstein, 2016; Hunt et al., 2011; 
National Research Council, 2001). In a recent example, in 2015, Nancy Campbell and David Herzberg 
hosted a U.S. symposium calling for the incorporation of gender analysis into critical drug scholarship 
(Campbell & Herzberg, 2017). Yet, such critical analyses remain a subset of U.S. drug research. As a 
result, conversations about drug use in the public sphere, including those among policymakers, media, 
researchers and the general public, reveal a wide variety of thinking about who uses drugs, why, and with 
what outcomes. Many researchers in the U.S. struggle with the prohibitionist model’s constraints and 
conditions, particularly its reductionist perceptions of drugs and people who use drugs through the lenses 
of criminalization and the medicalization of addiction (Hansen, 2017; Garriott, 2013; Alexander, 2011; 
Raikhel & Garriott, 2013; Clark, 2011; Granfield & Reinarman 2014; Reinarman, 2005; Hunt et al., 2007; 
Conrad & Schneider, 1992; Netherland, 2012; Hunt & Barker, 2001). Historically, much of this 
misunderstanding has been driven by racism, classism, and stigma about people who use illegal drugs and 
has resulted in punitive and largely ineffectual policies (McKim, 2017; Sales & Murphy, 2007; Mauer, 
1999). While elsewhere in the world there may be a “quiet revolution” happening within drug policy 
research (Brownstein, 2016), in the U.S. the community of critical drug researchers is relatively small and 
drug policy research remains largely bound by the ideologies of criminalization and medicalization 
(Netherland, 2012).  
These deeply entrenched ideological forces affect drug policy, in that “the fundamental 
inconsistencies of drug prohibition continue to be accommodated in policy reform” (Taylor, Buchanan, & 
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Ayres, 2016, p. 453). We argue that the same can be said of the vast majority of drug policy and addiction 
research in the U.S.: because it accommodates and functions within the prohibitionist framework, it has 
limited effectiveness in producing new ideas or in helping propel forward needed changes. Indeed, 
Lancaster (2016) has pointed out that the “evidence” produced by researchers does not sit outside of the 
policy process but that policy processes and evidence are interrelated, each helping to enact the other. 
What we mean by “addiction” or “drugs” is constantly in flux, reflecting contemporary understandings 
and sociopolitical debates far more than any truths inherent in those concepts (Fraser, et al., 2014; 
Netherland, 2012).  Often, U.S. research on drug policy and addiction reinforces the assumptions of the 
policy and cultural framework in which it is situated resulting, for example, in an over-emphasis on 
abstinence-only or prohibition-related outcomes with a focus on pathology, loss of control, and the harms 
associated with “problematic use" (Hunt & Barker, 2001; Heather, 2017; Frank & Nagel, 2017). At the 
same time, this frame and related drug policy research ignores the vast majority of drug use that is 
recreational and functional, while taking for granted the arbitrary lines drawn between legal and illegal 
substances. In the U.S., the ways in which prohibition has constituted a cultural understanding of drugs 
and users continue to produce problems with particular meanings, “problems” that reinforce assumptions 
about drugs and users rather than open new solutions at the state and federal levels (Bacchi, 2012). This 
understanding of drug policy as one site in which “the politics and materiality of drugs are made,” (Fraser 
& Moore, 2011, p. 500) reflects the indeterminacy of “drugs” and “users,” even as it acknowledges the 
dominance of prohibitionist knowledge production. 
Additionally, how research informs policy poses particularly challenging systemic issues in the 
U.S. (Gstrein, 2017; Stein & Daniels, 2017; Daniels & Thistlewaite, 2016; Brownstein, 2013). Almost 
two decades ago, the U.S. National Research Council’s (NRC) comprehensive report argued that the 
nation’s data and research programs were “strikingly inadequate to support the full range of policy 
decisions that the nation must make” (NRC, 2001, p. 1). Little has changed to improve the “woeful lack 
of investment in programs of data collection and empirical research” about drug use to assess and inform 
drug policy (NRC, 2001, p. 1, 7). Despite recognized limitations in methods, common data sets like the 
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National Survey on Drug Use and Health (NSDUH) continue to be the standard in U.S. drug policy 
research (Barratt et al., 2017; Walker, 2017).  Beyond the kinds of evidence that are produced, the 
dissemination of research suffers from a lack of communication among the disparate organizations, 
disciplines, and individuals involved in drug policy research—much of it is shared with small, focused 
audiences (Campbell & Herzberg, 2017; Taylor, 2016; Kleinman et al., 2012; Peretti-Watel, 2011; Ritter, 
2009). Consequently, the use of research in policy-making is selective and tends to reinforce flawed 
understandings of both legal and illegal drugs and the people who use them (Du Rose, 2015; Sturgeon-
Adams, 2013; Hammersley, 2011; Ritter, 2009; Moore, 2008; Weiss, 1983). This self-reinforcing 
dynamic extends to public discourse in the U.S., where the stigma, misinformation, and myths about 
drugs and people who use drugs persist, repeated even by reputable media outlets (Walker, 2017; Swalve 
& DeFoster, 2016; Linneman et al., 2013; Reeves & Campbell, 1994; Reinarman & Levine, 1989). The 
highly-politicized nature of drug policy reform, fed by a knowledge-deficit about drugs and the people 
who use them, has led U.S. decision makers to largely reproduce the uninformed thinking that epitomizes 
failed drug policies.  
What has been missing in the U.S. is a research agenda that attempts to address the systemic, 
fundamental fallacies of the prohibitionist framework. Gstrein (2018), in a scoping review of social 
construction and ideation research in drug policy, defines drug policy as “government policy that 
addresses issues arising from the use of illicit drugs, with a particular focus on health outcomes” (Gstrein, 
2016, p. 76). We use “drug policy research” here to refer to this domain but also include research that 
concerns addiction, treatment, harm reduction interventions, drug supply and markets, and drug-related 
criminal justice research. Despite the emergence of research contesting reductionist notions of drugs and 
people who use them—more broadly outside of the U.S. but also as a minority voice within U.S. research 
(see for example, Granfield & Reinarman, 2014; Raikhel & Garriott, 2013; Hunt et al., 2011; Moore, 
2008; Reinarman, 2005; Campbell & Herzberg, 2017; Campbell 2002, 2007; Netherland, 2012)—
dominant drug policy discourse in the U.S. continues to impede complex understanding of drug-related 
issues, perpetuating a research culture that confirms normative assumptions that drugs are a threat and 
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precludes alternative knowledges and more holistic research programs. To make more effective 
interventions in the widespread effects of prohibitionist thinking, Taylor (2016) calls for a “collective 
action by critical scholars to contest these damaging processes,” for scholars to move forward with 
innovative research agendas, and for scholars to “go public” even when they risk being “othered” and 
devalued (Taylor, 2016, p. 101).   
To focus on addressing these issues as well as answering the call for innovative research in the 
U.S., we initiated a project entitled, UnBounded Knowledge: Envisioning a New Future for Drug Policy 
Research (UBK). As a collaboration between a cultural studies scholar and a social scientist with a 
background in public health research, UBK brought concerns from those fields about the social 
construction of drugs and users to bear on the question of how U.S. drug policy research could be 
influenced to challenge (and think beyond) the cultural bounds of drug criminalization and 
medicalization. We also wanted to consider ways to approach related constraints within the U.S. research 
context, such as the lack of centralized data repositories, the absence of nationalized healthcare and 
attendant records, and the current inability to link administrative data systems at the level of individuals. 
The project included a diverse group of multidisciplinary drug researchers in a focused collaboration to 
identify what drug research in the U.S. should be (but is not) studying absent these constraints. UBK 
engaged this group of researchers through interviews and a structured, collaborative conversation to 
articulate ways to move past specific research barriers to create more interdisciplinary studies in areas that 
were identified as opportunities for and most critically in need of change. Through this project, we 
identified several key areas that would begin to move U.S. research beyond the current constraints, 
including new ways of doing drug policy research and specific research projects that would help shift 
U.S. policy in new directions.  In this article, we report on the project, particularly its emphasis on how to 
better inform research gaps in the U.S. through a collaborative, interdisciplinary approach.  
 
U.S. Research Environment  
  Drug policy research in the U.S. has been shaped, not only by the cultural context of stigma and 
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biases about people who use drugs, but also by systemic issues that have reinforced the prohibition 
model, such as how drug research is designed and funded, how academic incentives and organization 
shapes research, and a variety of methodological limitations within drug research practices. Critical drug 
scholars, largely outside the U.S., have focused on the ways in which the roles of stakeholders, ideas, 
politics, and public discourse co-construct drug policy and its conception of drugs and users (Gstrein, 
2018; Thompson & Coveney, 2018; Lancaster et al., 2018; Race, 2017; Smith, 2016; MacGregor, 2013; 
Fraser & Moore, 2011). Such scholarship theorizes working more fluidly with the conceptual framework 
of evidence-based policy (EBP), pursuing ontological and epistemological questions about what and who 
constitute knowledge and evidence, and proposing “a post-evidence based approach to policy analysis” 
(Gstrein, 2018, p. 83). With drug policy research evolving in these theoretical directions elsewhere, we 
might ask how the U.S. drug policy research community remains somewhat entrenched in the EBP model 
and seems challenged to address its policy environment.  
 Two documents, produced sixteen years apart, help illustrate some of the ways in which drug 
policy research in the U.S. has trouble identifying, much less critiquing, the prohibitionist framework that 
frames and helps produce it. The 2001 NRC report for the Office of National Drug Control Policy 
(ONDCP), laid out a series of recommendations for improving drug policy research in the U.S. While the 
report covers an astonishing amount of terrain, its primary conclusions were to invest in infrastructure and 
data systems to better assess illegal drug consumption and the effectiveness of enforcement policies 
aimed at drug users. Written in service of the ONDCP at a time when billions of dollars had already been 
spent on punitive drug policies resulting in the mass criminalization of hundreds of thousands of 
Americans, the authors call for better and more diverse evidence to support or challenge the effectiveness 
of those policies. However, they fail to challenge the fundamental drug war framework by, for instance, 
interrogating the arbitrary divisions between illicit and legal substances or calling for research into the 
underlying motivations or root causes of drug use. Even their nod to a reduction of the demand for drugs 
is focused on evaluating the effectiveness of sanctions to reduce demand. While the report recognizes 
limitations inherent in the ONDCP’s criminalization policy, such as the desirability of having better data 
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about drug consumption, the NRC review is restricted in its ability to question some of the fundamental 
fallacies and assumptions undergirding it (NRC, 2001, pp. 3, 6, and 11). This is not surprising at a time 
when the ONDCP’s budget tripled, escalating funding for the war on drugs and anti-drug media 
campaigns (ONDCP H11225, 1998). 
 In 2018, more than fifteen years later, the key funders of drug research in the U.S., the National 
Institutes of Health (Courtwright, 2010; Malizia & Ferro, 2014), received an additional $500 million from 
Congress to address the opioid overdose crisis. In the research plan for the HEAL (Helping to End 
Addiction Long-Term) initiative, the NIH writes that it intends to focus on medications for treatment, 
overdose prevention and reversal; neonatal abstinence syndrome; non-addictive medications and 
alternative treatments to pain; and optimizing treatments for opioid use disorder with a focus on the 
expansion of medication assisted therapies (Collins, et al., 2018). While all laudable goals, this research 
plan, like the one proposed by the NRC, likely does little to disrupt a policy framework that remains 
rooted in a narrow individualistic approach overly focused on the end point of addiction, one that does 
little to account for (much less intervene in) the social determinants of drug use, or employ additional 
harm reduction interventions proven effective internationally, such as safer consumption spaces or heroin 
assisted treatment.  
 This challenge to establish a more expansive and critical research agenda in the U.S. is perhaps 
not surprising given that, in the U.S., drug research funding often comes with particular ideological purse 
strings. In addition to the federal mandate to sustain drug prohibition, the funding of drug policy research 
is tied not just to the drug war but to its twin logic, a medicalized understanding of drug use as addiction. 
The vast majority, up to 80%, of drug policy research is funded by the National Institute on Drug Abuse 
(NIDA) (Malizia & Ferro, 2014), whose mission and scope are narrow: “to lead the Nation in bringing the 
power of science to bear on drug abuse and addiction (Volkow, 2011).” NIDA’s emphasis on addiction 
neuroscience has become a primary area in US drug research (Campbell, 2007; 2010; Reinarman, 2005). 
Sociologist Scott Vrecko describes NIDA as largely responsible for making “the neuroscientists’ 
laboratory...an obligatory passage point for the production of truths about addiction (2010: 58).” NIDA’s 
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overemphasis on the brain de-emphasizes other systemic factors influencing drug use, such as poverty, 
racism, and the social environment (Hansen & Netherland, forthcoming). A review of their 2016-2020 
strategic plan reveals that NIDA generally does not intend to fund projects that examine harm reduction 
interventions, the therapeutic potential of drugs such as cannabis, or the harm associated with current drug 
policies grounded in abstinence, the threat of punishment, or its collateral consequences (NIDA, undated). 
For example, the words “harm reduction” appear nowhere in the sixty-page strategic plan. Rather, NIDA 
spent 43% ($438.1 million) of its budget on basic and clinical neuroscience, 25% ($252 million) on 
epidemiology, services and prevention research, and split 13% ($131.9 million) between medications 
development and research into how specialists in infectious diseases common among people who use 
drugs can help screen and provide interventions for addiction. The remaining 19% ($193.7 million) went 
to intramural research, support for a clinical trial network, and administrative support (Koch, 2015).  
 Some have argued that the National Institutes of Health’s extramural funding system, including 
NIDA, creates another problem: it favors more experienced researchers over younger ones and more 
conservative projects over more innovative ones. According to an essay by four scientists, including 
Harold Varmus, MD, Nobel Prize co-recipient and once director of the National Institutes of Health, “The 
system now favors those who can guarantee results rather than those with potentially path-breaking ideas 
that, by definition, cannot promise success” (Alberts et al., 2014, p. 5774).  
In addition to issues of focus and funding, the field of U.S. drug policy research faces a number 
of methodological limitations, in part, stemming from the policy context that shapes it. For example, there 
is a considerable focus on the most extreme drug use (addiction) and its treatment to the exclusion of 
other drug use and natural recovery (Decorte, 2011; O’Malley & Valverde, 2004; Sobell et al., 2000; 
Granfield & Cloud, 1999). The lack of a broad view of drug use means U.S. research consistently forgoes 
understanding the vast majority of people who use drugs, those who are self-regulating, and their 
motivations and concerns (Askew & Salinas, 2018; Kiepek & Beagan, 2018; Race, 2009; Race, 2017; 
Walker, 2017; Fraser, 2008; Duff, 2004). Also, in the U.S. policy context, there is often a failure to 
adequately include and involve those directly impacted by drug use or drug policies in research design, 
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collection, and interpretation of data based, in part, on stigma and assumptions about the inability of 
people to use drugs to engage meaningfully in such activities produced (Lancaster et al., 2018; Jurgens, 
2005; Osborn & Small, 2006).  
Taken together, all of these issues present a significant problem: they outline the context of what 
we in the U.S. can and do collectively “know” about drugs, the impact of our drug policies, and how to 
best respond to both ongoing and emerging drug-related problems. A significant challenge in the U.S. 
research environment is the self-fulfilling hold that the prohibitionist model has on many aspects of the 
drug policy landscape, from policy and funding to public health and public opinion. For example, in the 
midst of the current opioid overdose crisis, despite the emergence of interest in harm reduction strategies, 
the U.S. policy response to illegal drug use continues to be driven by prohibitionist and medicalized 
contexts. The federal government has doubled down on criminalization through mandates such the 
Department of Justice’s memos to “combat this deadly [opioid] epidemic” by urging federal prosecutors 
to “consider every lawful tool at their disposal,” including “seeking capital punishment for certain drug-
related crimes” (U.S. Department of Justice, March 2018). This followed a memo in which the 
Department of Justice urged prosecutors to pursue marijuana violations to the fullest extent of the law 
(U.S. Department of Justice, January 2018). Further, because public drug discourse in the U.S. cannot 
seem to escape medicalization’s logic of illegal drug use as harmful and drug addiction as requiring 
abstinence as a solution, harm reduction is a non-starter at the federal level. Instead, the focus is on 
reducing supply and addiction treatment (President’s Commission on Opiate Disorders, 2017). While a 
handful of the states hit hardest by the opiate crisis are attempting to implement needle exchange 
programs and open safe consumption sites, such harm reduction measures struggle to win public support 
at the local level precisely because they are not seen, as Helen Keane argues in other contexts, as value-
neutral in the moralized arena of drug debate (Keane, 2003). 
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UnBounded Knowledge Project 
 The UnBounded Knowledge project was designed as a deliberate attempt to generate fresh 
thinking about the future of U.S. drug policy research in ways that would address the confines of the 
prohibitionist and addiction-focused medicine frames that have dominated the field. While the premise of 
the project is founded in the scholarship that demonstrates particular gaps and biases in U.S. drug policy 
research landscape, we in no way mean to suggest that there is not excellent research being done in the 
U.S. and abroad that provides counterexamples and critiques to the U.S. prohibitionist framework. Nor 
did we construct this as a formal, disciplinary research study. Rather, the project was an attempt to be 
broadly generative in developing applied projects that would address the interstices and absences in 
current U.S. drug policy research. We acknowledge that UBK was informed by a certain political 
sensibility and that the project was intentionally framed to invite researchers to partner in a different kind 
intervention or problem-solving. If “evidence” is not fixed, but constituted in part by specific 
performances and practices (Lancaster, 2016), our hope was to invite and explore less dominant or 
conventional performances and practices. In particular, there are few opportunities in the U.S. for truly 
interdisciplinary drug research (Kushner, 2006; Dunbar, Kushner, & Vrecko, 2010) and, thus, the 
knowledge generated is frequently bound by disciplinary siloes as much as by the prohibitionist context in 
which we work.  
 UBK was conceived of and implemented by a university-based researcher and the Drug Policy 
Alliance (DPA), an advocacy organization whose mission is “to advance those policies and attitudes that 
best reduce the harms of both drug use and drug prohibition, and to promote the sovereignty of 
individuals over their minds and bodies (DPA, 2018).” In this sense, UBK was a deliberate attempt to 
collectively envision a research agenda that could imagine and work in a context beyond the frame of 
prohibition and to encourage participants to think expansively and in a multiplicity of ways about 
potential research that would improve U.S. drug policy. We thought a multi- and interdisciplinary 
collaboration across what are often epistemic or disciplinary boundaries would illuminate new ways to 
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address longstanding, systemic issues in drug policy research in the U.S. Our hope was to model a new 
way of working for U.S. drug researchers. 
 The project consisted of three distinct parts: 1) a preliminary series of interviews with researchers 
and drug policy-related professionals, 2) the identification of common research constraints and a set of 
factors that would transform the direction of drug policy research and, 3) a day-long workshop to craft an 
aspirational research agenda built on this foundation. The project’s goals were to illuminate the problems 
in the current drug policy research landscape from a multidisciplinary perspective, imagine what drug 
policy research could and should look like, and develop a core of multidisciplinary researchers who might 
take this conversation back out into a variety of research contexts. Our ultimate objective was to start a 
dialogue within the drug research and research funding communities in order to begin to shift the kinds of 
research that is funded and conducted. Over the summer and fall of 2017, we interviewed more than 30 
professionals, mostly from the field of research, whose work informs or reflects drug policy. Participants 
were selected to include individuals from a wide array of disciplines, stages of career, and settings. We 
sought individuals whose work is characterized by fresh thinking and applied solutions and whom we 
believed would welcome stepping outside the dominant U.S. research paradigm as well as collaborating 
freely across disciplines and areas of expertise. We selected participants in consultation with a committee 
of researchers from harm reduction, sociology, social work, drug policy, and gender studies. The 
participant group was crafted with special attention to perspectives that are often not well-represented in 
U.S. drug policy—such as the perspectives of people who use drugs—eventually creating a group of 
researchers, researcher/clinicians, and a journalist working at the intersection of science and drug policy. 
In designing the project, we had in mind methods akin to that used by David Nutt (2010), who convened a 
group of experts to help establish a framework for determining drug harms. Consensus methods have long 
been used in health and health services research, particularly for controversial topics. Our project also 
draws on the nominal group process in which participants are first asked to answer questions individually 
and then brought together for a structured group discussion (Jones and Hunter, 1995; Fink et al, 1984). 
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To gather individual answers, we conducted 30 one-on-one interviews by phone and a follow-up 
email. We asked participants to reflect on what factors currently constrain drug research in the U.S. and, 
as a result, what researchers currently do not know but should seek to learn. Using a semi-structured 
guide, the two authors of this manuscript conducted the interviews, which lasted between 45-60 minutes. 
The interview guide consisted of five questions about limitations and gaps in the current research 
environment, focusing upon gaps in the research, methodological issues, funding problems, and sources 
of bias in the research. For most of the interviews, a second staff person sat in on the interview and took 
notes. The interviews were not recorded or transcribed but were well-represented in extensive notes, 
which were then analyzed by the interviewers, along with the broader project team, to identify the key 
themes.   
Researchers have debated the advantages of tape recording interviews (see for example, Weiss, 
1995; Halcomb & Davidson, 2006; Cachia & Millward, 2011). We opted not to tape or transcribe our 
interviews due to the specific nature of this project. First, our request to participants to identify a 
significant set of constraints on research asked them to, potentially, be critical of the very systems in 
which they work (editorial boards, federal grant fund sources, etc.) and so we kept comments anonymous 
to increase their comfort and candor. Second, because we were asking participants to identify a systemic 
set of factors—the barriers they faced, the gaps they saw, and the methodological issues they observed—
our interest was in capturing major themes and ideas rather than analyzing transcripts for a detailed 
textual or discourse analysis. Note-taking more than adequately captured these responses. Participants’ 
responses provided a rich body of material from which to better understand various individual and shared 
factors that limit drug policy research. These data were developed into a “summary of constraints” and 
represent a significant set of problems that U.S. researchers commonly identified as limiting their work. 
This summary document was then sent to all participants so that they had the opportunity to review the 
summary we prepared to ensure that the summary accurately reflected their views, correct any 
misinformation, and/or add additional information.  
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 Following the interviews, we shared the summary of constraints with participants and then asked 
them to propose three key changes that would improve and transform U.S. drug research and policy. 
From that set of factors, we devised a summary of improvements to the research environment. The two 
documents, outlining constraints and potential improvements, became the foundation for a day-long 
workshop on what kinds of research are most needed and, specifically, how to design and manifest a more 
effective research agenda. Our goals for the meeting were to: 1) work with the group collaboratively to 
create specific, actionable strategies for resolving research barriers, 2) articulate an aspirational list of 
research projects, and 3) highlight areas for immediate action.  
In December of 2017, 25 researchers met in Washington, D.C. for the third phase of this project.  
This group included most of the original interviewees (some were not able to attend) as well as additional 
participants selected to create a multidimensional, representational, and interdisciplinary group that 
included one perspective external to the U.S. Attendees represented all points in their careers, from 
graduate students to emeritus professors and included a variety of perspectives involving quantitative and 
qualitative research, public health and health care practice, journalism, and policy-making. In addition, 
the participants’ areas of expertise in research and practice focused on a wide range of topics from various 
methodologies and represented the fields of anthropology, clinical psychology, criminology, cultural 
studies, epidemiology, geography, history, law, methodology/statistics, media studies, medicine, public 
health, public policy, psychiatry, and sociology. Participants worked in various small groups (both 
random and self-selected by topic) in addition to working together as a whole. Through a two-part 
framework, we first asked participants to collectively build on the identified constraints to clarify what 
factors would most transform those limitations. Then, in four smaller groups, participants collaborated to 
create a list of projects that would form an aspirational research agenda. Finally, from the latter list, 
participants self-selected into different topic groups briefly developed a multidimensional, ideal research 
project to disrupt current barriers in drug policy research.  
The information generated from the meeting was recorded in extensive notes as well as through 
the use of a graphic recording service, which translated conversations into images and text on large sheets 
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of paper as the meeting took place. Participants were invited to review and correct notes and the graphic 
recording on-site as well as to comment on a summary of the proceedings provided to them shortly after 
the meeting.  
 
Moving Forward: Unbinding Knowledge 
 Participants in UBK generated a body of ideas about how to address current research constraints 
to move U.S. drug policy forward. Most notably, the meeting highlighted the importance of working in 
interdisciplinary research clusters to shape research design and outcomes across academic, organizational, 
public health, and health care practice domains. Perhaps the strongest finding from the project was the 
desire and need for more discussion of drug policy research across disciplines, with several attendees 
noting how their own thinking and work had been deepened by just one day of being exposed to other 
perspectives. The group came up with dozens of concrete suggestions that, while they may not be new in 
a global context, have simply not been centered in the U.S. drug research environment: from developing 
rapid-response grants to deal with emerging drug-related crises, to studying poly-drug use or changing the 
outcomes measures used to assess drug treatment and other intervention studies. Some of these 
recommendations may appear to be in tension with one another. For example, there was a strong 
emphasis on the need to look at the effects of structural forces but also a recommendation for more 
research on how individuals themselves manage drug use effectively. Such variations reflect a recognition 
of coexisting tensions between structural factors and the role of individual agency in drug use. There is a 
need for drug research that can inform policies at multiple levels, from individual interventions to policy 
change, with a recognition of the reciprocal relationship between micro and macro level forces. In a study 
that broadly explored needed areas for research, the recommendations focused on gaps that, when 
informed with data, may produce different policy opportunities. Participants acknowledged that, even as 
they push for visionary and sweeping change, incremental steps are needed to get there. 
We focus first on “Different Ways to Research,” recommendations that outline strategies to 
surmount systemic boundaries and limitations in the U.S. research environment, changes that would also 
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disrupt current research paradigms to generate more innovative projects. Next, we discuss  “Research 
That Would Change Drug Policy,” topics primarily related to the group’s efforts to work beyond the 
individualist, prohibitionist, and addiction-focused frames in U.S. drug policy research. Specifically, these 
recommendations call for broader levels of analysis and deepening research on substance use in ways that 
challenge the narrow, but dominant, view of drugs as inherently dangerous. As a whole, this research 
outline has the potential to interrogate some of the primary myths and underlying fallacies of the 
prohibitionist frame that Taylor et al. (2016) identify, such as the belief that substances are currently 
categorized according to some scientific rationale, drugs inherently cause crime and social problems, 
continued drug use inevitably leads to addiction, and drug use has no place in a civil society. Based on the 
constraints generated from our interviews, we would add the fallacy that drug problems are fundamentally 
caused by individual behavior and choices as well as the failure to widely study harm reduction 
interventions, self-regulated drug use, and policy-level interventions.   
 
Different Ways to Research 
 The strongest consensus to emerge from the meeting was the need for new ways of working in 
U.S. drug policy research. At the top of that list was the desire for interdisciplinary forums, such as the 
one created by the project itself. Participants agreed that many significant barriers to actionable and 
effective drug policy research are structural, including the mandate to work within a discipline (Campbell 
& Herzberg, 2017; Kushner, 2006, 2010; Dunbar et al., 2010). Further, the structure of academic and for-
profit funding, research, and publication distances researchers from the immediacy and impact of policy 
on people who use drugs and their needs (Stein & Daniels, 2017).  Putting a diverse group of people from 
fifteen different disciplines and all stages of career in a room together necessarily complicated issues in 
productive ways. The impetus for UBK was a recognition that drug policy problems in the U.S. are 
complex and multifactorial and as such, require deep thinking from multiple perspectives in conversation 
with one another. Inviting participants to problem-solve across disciplinary and professional domains led 
to a critically robust and collaborative discussion of research issues and potential solutions, including 
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their immediate impact on people who use drugs and those who work with them. Specific 
recommendations for improving the ways of doing drug policy research in the U.S. include: 
 
Build Interdisciplinary Partnerships (especially between qualitative and quantitative researchers): 
Academic and professional silos, as well as the diverse and sometimes conflicting policy contexts of 50+ 
state and federal arenas, limit our ability to understand and contextualize the research we conduct. Multi- 
and interdisciplinary research is urgently needed. Many of the projects designed by the UBK participants 
required interdisciplinary teams working together in multi-stage studies. Creating pathways for those 
collaborations and partnerships is a critical first step. Identifying the most suitable venues for this kind of 
work is a key second step. Research engaged across disciplines and organizations would lead to more 
nuanced ways of tackling both long term and immediate needs (see also, Bourgois, 1999, 2002; Rhodes et 
al., 2010).  
 
Redesign the Research Environment: The research process in the U.S.—from its structure, funding, 
design, and publication—needs to be modified. Structures of funding, research incentives, and career 
demands in academic and for-profit settings foreclose on the issues researchers might prefer to study, 
including topics that they believe would contribute to better drug policy. Participants underscored the 
need for publication outlets that serve policy-oriented outcomes, such as journals and other platforms that 
invite multi- and interdisciplinary scholarship. Specifically, participants identified a need to challenge the 
structure and incentives within academia to promote more innovative research as well as scholars’ role in 
communicating to the media, the public, and policymakers–ideas that appear to be gaining more currency 
in academia (Daniels & Thistlewaite, 2016; Stein & Daniels, 2017; Badgett, 2016). These include 
strategies to teach and reward public scholarship and media work, develop forums for interdisciplinary 
work, and transform the peer review process to make it more constructive, rapid, and interdisciplinary. 
They also recommended creating new publication outlets, such as additional policy-oriented journals, 
journals for interdisciplinary and qualitative work, and accessible platforms for public-facing scholarship 
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about drug use and drug policy. These kinds of strategies would help push past existing barriers, open up 
more space for critical drug studies, and encourage the development of innovative research and policies. 
 
Incorporate Different Types of Expertise: Too much drug research employs assumptions and thinking 
shaped by criminalization and stigma by researchers with little experience with drugs and/or exposure to 
people who use drugs. Research should involve stakeholders as investigators (people who use drugs, 
community members, etc.) across the spectrum from research design and data collection to analysis and 
dissemination of findings (Lancaster et al., 2018.). Among the potential benefits of such inclusion are: to 
identify areas for research unseen by people who do not use drugs, disabuse the research community of 
such mischaracterizations, and lift the silence on talking freely about illegal drug use practices—
especially with regard to pleasure—and as a matter of social justice.  
 
Diversify Funding Resources and Objectives: Not surprisingly, participants had a number of 
recommendations related to funding. These included more funding for innovative and exploratory work, 
access to rapid response grants, support for collaboration across disciplines (also across setting, research 
experience, or point in career), and backing for ethnographic and qualitative research as well as for 
modeling and cost effectiveness research. In addition, participants noted the need to fund younger or less-
represented scholars—particularly women, people of color, and those impacted directly by the war on 
drugs—who often bring a much-needed fresh perspective.  
 
Work to Reschedule Drugs, such as Cannabis and Psychedelics, to Promote Research on Their 
Therapeutic Uses: Current drug schedules in the U.S. are problematic for a variety of reasons, but 
particularly because of the lack of research underlying their categorization of drugs. Research is needed to 
address both the therapeutic uses and potential harms of substances is impeded by these misguided 
categorizations. A strategy to make schedule 1 drugs more accessible for research is essential to improve 
the knowledge base about scheduled drugs (see also, Doblin, 2000). 
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Alter the Metrics for Intervention Studies: In regard to intervention studies, the group recommended 
focusing on outcomes beyond reductions in or cessation of drug use and recidivism, such as quality of 
life, housing status, employment, family reunification, and client satisfaction and preferences.  
 
 
Research That Would Change Drug Policy 
 
In addition to changes in how drug researchers work and how the drug research environment is 
structured, participants broadly agreed on content areas that require greater focus. Participants chafed 
against the current emphasis in U.S. drug policy research on narrow, individualistic approaches that fail to 
contextualize drug use, its harm, and the harms and benefits of the interventions we employ to address it 
and how that focus contributes to a policy discourse that roots the solution to drug problems in addressing 
individual pathology through either criminalization or medicalization. Similarly, they commented on the 
relatively few studies that assess policy-level interventions or studies looking at international issues, such 
as how U.S. policy impacts other countries and global drug policy, and discussed the ways in which this 
gap may contribute to the failure of policymakers, the media, and the wider public to fully consider the 
implications of the U.S. drug policy abroad. Overall, they called for a broadening of perspective and 
scope, one that would necessitate the kinds of interdisciplinary approach described above. 
Recommendations for specific, much-needed areas of drug policy research in the U.S. are as follows: 
 
 
Structural Issues: Expanding the Levels of Analysis 
  
As noted above, the majority of research on drugs in the U.S. focuses at the level of individual drug use. 
These studies are critically important to understanding who uses drugs and why, but they are insufficient 
for providing policymakers and the public the information needed to respond effectively to drug 
problems. While the term “problematic use” can itself be problematic, we are using it here to 
acknowledge that drug use happens on a spectrum ranging from experiences that can enhance one’s 
 19 
functioning to those which can create substantive problems (albeit often exacerbated by social 
circumstances). Participants urged more research on the structural and social conditions (i.e., racism, 
network impoverishment, and other forms of oppression) that contribute to problematic drug use and/or 
support abstinence or functional drug use. Social determinants of drug use have received some attention 
internationally (see for example, Spooner & Hetherton, 2005) and in the U.S., (see for example, Galea & 
Vlahov, 2002; 2003). Although difficult to measure and study (NRC, 2001), in part, because of the 
complex interplay of factors, tackling some of the challenges of doing so could help us get to the root 
causes of problematic drug use, encouraging policymakers to intervene further upstream. For example, 
how do access to housing, education, employment, social cohesion, incarceration, or community 
institutions impact drug use? Researchers in Canada, for instance, found that injection drug users with 
unstable housing were more likely to end up in emergency departments and called for stable housing as a 
potential policy solution (Palepu et al.,1999). Why do certain subpopulations in a particular region 
struggle more with resolving substance use issues? For example, Gossop et al. (2000), looking at routes of 
administration among people seeking drug treatment in England, found significant regional variations that 
had implications for how policymakers and providers approached prevention and treatment as well as for 
health officials distribution of services, such as vaccination hepatitis B. Through interdisciplinary 
partnerships, between qualitative and quantitative researchers, participants projected ways to move from 
broad structural issues to sub-populations about which we know very little.  
To provide a more concrete example from the UBK meeting itself, one of the smaller UBK 
working groups focused on the lack of research that examines how community- and structural-level 
factors impact drug markets and drug use. They were interested in understanding how and why certain 
drugs enter a community and whether or not there are community-level factors that deter the introduction 
of drugs and/or their use once introduced. Why, for example, do some communities have high opioid 
overdose rates, while others do not? Focusing on fentanyl, they suggested comparing two jurisdictions 
with different overdose rates and examining a range of factors to better understand what factors impact 
the market for and use of fentanyl. For instance, they would use mixed methods (qualitative and 
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quantitative) to examine the role of law enforcement, social services, housing and employment 
opportunities, and other factors. Working with historians, they would try to better understand the drug 
markets, how new drugs are introduced to the community, and what political and community forces might 
be at play. This research could lend insight into what kinds of policy and community factors might 
impede or mitigate the introduction and spread of drugs within communities as well as harmful drug use. 
Just as we need to know more about the structural factors impacting sales and use, so too, we 
need to know more about the effectiveness of policy interventions at the macro level. While some studies 
are emerging about marijuana legalization (see for example, Cerda et al., 2012; Pacula et al., 2015; 
Bachuber et al., 2015), and there are a small number of studies about supply-side policies used to address 
the opioid overdose problem in the U.S. (see for example, Baehren et al., 2010; Buchmueller & Carey, 
2017), participants encouraged more research and evaluation of policy interventions as they unfold, 
including studies of “natural experiments.” Policy changes and practices beyond cannabis legalization—
such as Good Samaritan Laws, naloxone access, drug induced homicide prosecutions, drug checking, 
expanded access to treatment—are being rapidly implemented, but studies of these interventions and their 
effectiveness are scarce (see for example, Bardwell & Kerr, 2018).   
 
Deeping and Broadening Understandings of Substance Use 
Perhaps nothing has shaped U.S. drug research more profoundly than the pervasive belief that illicit drugs 
are inherently harmful and addictive. The pathologizing of drugs and the people who use them influences 
our assumptions about motivations for drug use, the kinds of questions we ask, whom we study, and the 
outcomes we measure. Moreover, these kinds of logics and discourse undergird the neoliberal project of 
governing pleasure as well as the demonization and criminalization of those who use “demon drugs” 
(Walker, 2017; Race, 2009; Reinarman & Levine, 1997; O’Malley & Valverde, 2004). The intense focus 
on the harms of drugs in the U.S. has meant we know relatively little about their therapeutic and 
recreational uses or about the vast majority of people who stop using drugs on their own (Sobell et al., 
2000; Granfield & Cloud, 1999). There were three areas identified for more focused research on 
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substance use: self-regulating drug use, the positive motivations for and outcomes of drug use, and better 
understanding of poly-drug use.  
 Participants noted we have much to learn from the vast majority of people who use drugs 
functionally. In addition to structural factors, what is it about self-regulating drug use that might become 
part of drug use education and harm reduction strategies? The potential benefits of studying normative 
drug use and self-regulating drug use are enormous. They can lend insight into why and how most people 
who use drugs can control their use and how many of those who cannot control use quit on their own 
(natural or spontaneous recovery). Research topics would include what kind of calculations or incentives 
motivate people to regulate or stop use, what resiliency or assets do people have or need to moderate drug 
use, and what motivates their use in the first place. By focusing on “problematic” drug use, we have 
learned much about the problem but not much about preventing it or what might be the most effective 
solutions. This area of research has great promise to lead us to new ways of approaching more severe and 
consequential drug use as well as better understanding a broader spectrum of drug use. 
 One of the major artifacts of prohibition is that we have little research about why people use 
drugs, the net-benefit of drug use, and the outcomes sought by people who use drugs. Research that 
addresses pleasure, life management, drug use for spiritual and health benefits, etc. would begin to fill in 
a cultural picture of the motivations for most drug use and allow policymakers to make more nuanced 
decisions about how and why they intervene in the consumption of drugs. 
 While most people who use drugs do not use a single drug at a time, drug policy research in the 
U.S. often isolates substance use by drug. People who use drugs may combine alcohol, opiates, 
stimulants, and benzodiazepines—some of which people who use drugs are not even aware will interact 
with other drugs. Indeed, some of the overdose deaths in the current opioid overdose crisis are the result 
of poly-substance use—mixing opioids with a deadly combination of alcohol and/or benzodiazepines 
(Park et al., 2015; Jan et al., 2014; Jones & McAnich, 2015). The opiate overdose crisis is just one 
example of a critical cultural and policy need for a better understanding of poly-substance use. With the 
proliferation of novel psychoactive substances ranging from spice to fentanyl, research on the short- and 
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long-term health effects of using drugs in combination is urgently needed. Additionally, more studies that 




The participants in Unbounded Knowledge were emphatic that a better future for drug policy 
research in the U.S. requires researchers who can work collaboratively across boundaries of discipline and 
profession to answer the field’s most challenging and urgent questions. In a setting that itself attempted to 
model such collaboration, they articulated significant structural changes to drug policy research and 
conceptualized projects that would meet crucial informational needs. Given the opportunity to work 
across disciplinary and organizational domains, participants were highly motivated to join forces to 
change the conversation and transform research and policy in the U.S. With an understanding that the 
dominance of prohibitionist logic permeates drug policy research, the participants wanted to commit to 
projects that would make the problems inherent in that framework more visible while providing better 
data to address immediate needs. Collectively, they endorsed improvements to research contexts to, in 
turn, build a better knowledge base.  
We have highlighted just a few of the recommendations generated by the UBK project, and even 
the full spectrum of ideas that came out of the meeting are just a gesture toward what U.S drug policy 
research could become. We recognize that this was a select group that does not represent the drug policy 
research community in the U.S. and that the discussion would have been even richer had we been able to 
bring more international researchers to the table. Nonetheless, what the project demonstrated is both some 
of the problems with how U.S. research is currently conducted and the potential to reimagine drug policy 
research by bringing people together across disciplines and supporting them in thinking beyond the 
bounds that normally constrain them. 
While we understand that changing such pervasive systemic and institutional factors will not 
happen as a result of one project, we also recognize that the conversation needs to begin somewhere. We 
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share these findings in the hopes of furthering the dialogue about how to improve drug research in the 
U.S.—by addressing both long-term challenges and offering ideas that may be addressed sooner as low-
hanging fruit. In fact, the group generated several suggestions for advancing this agenda. These included 
using the findings to engage research funders – both public and private – in conversations about 
supporting more visionary projects; fostering conversations within academia, the media, and among 
policymakers about improving the field; instituting a recognition award to incentivize innovative, 
interdisciplinary projects; creating a virtual network of interdisciplinary critical drug scholars; training 
researchers to engage more directly with policy and funding change efforts; and developing additional 
forums for interdisciplinary work. Many of these suggestions are being taken up by the Drug Policy 
Alliance’s Office of Academic Engagement, which convened the UBK group. In addition, some 
participants plan to move ahead on the collaborations they conceptualized at the meeting – even absent of 
additional funding and support. 
It remains to be seen whether or not a small project like this can begin to shift entrenched systems 
and beliefs in the U.S. that structure how drug policy research is funded and conducted. The prohibitionist 
frame as well as the pull to individualize the problem of addiction are strong in the U.S. and are being 
bolstered in some ways by the current a political climate – including federal leadership that is dismissive 
of research in general. Nonetheless, there are also signs of tremendous opportunity, including a new 
interest in more progressive responses to the opioid overdose problem, driven in part by the racial politics 
of the problem (Netherland & Hansen, 2016, 2017), as well as what appears to be a resurgence of interest 
in scholar-activism and the publicly engaged researcher (Daniels & Thistlewaite, 2016; Stein & Daniels, 
2017; Badgett, 2016). If the enthusiasm and commitment of the UBK participants is any indication, there 
seems to be a motivated cadre of critical drug scholars in the U.S. ready to work in new ways and to 
shape a new research landscape – one that can do more to critically interrogate the dominant and 
destructive ideologies that drive much of the U.S. drug policy. 
The challenge remains to make the cultural changes that will help bridge disciplinary and 
organizational silos and support collaborative cross-disciplinary work to better inform and bring more 
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rationality to U.S. drug policy. To that end, the project drove home the need for spaces and funding to 
support interdisciplinary research networks and concrete projects, especially because so many of the 
policy problems that need to be solved are multi-faceted. Many of the most urgent and compelling 
questions in drug policy can only be answered through interdisciplinary approaches, and yet there are too 
few forums or incentives for researchers to engage in this way. The group recognized that to help solve 
some of the country’s most vexing drug policy problems, we need collaborations that are not supported 
by current research structures, funding, and outlets. In the spirit of the project, we invite a conversation 
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